Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01826448 |
| Title | A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | Plexxikon |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | FRA | DEU |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| UCLA | Los Angeles | California | 90024 | United States | Details | |
| University of Colorado, Denver | Aurora | Colorado | 80012 | United States | Details | |
| Vanderbilt University | Nashville | Tennessee | 37232 | United States | Details | |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | United States | Details | |
| Institute Gustave Roussy | Paris | France | Details | |||
| University Hospital Essen | Essen | Germany | Details |